- Home
- FMST vs PASG Comparison
FMST vs PASG Comparison
Compare FMST & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMST | PASG |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Canada | United States |
| Employees | 2 | 27 |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.5M | 26.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FMST | PASG |
|---|---|---|
| Price | $1.56 | $5.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 125.2K | ★ 144.3K |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.51 | $0.29 |
| 52 Week High | $5.74 | $20.00 |
Technical Indicators
Market Signals| Indicator | FMST | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 41.70 |
| Support Level | $1.53 | $3.94 |
| Resistance Level | $2.52 | $7.76 |
| Average True Range (ATR) | 0.15 | 0.46 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 16.12 | 64.46 |
Price Performance
Historical ComparisonAbout FMST Foremost Lithium Resource & Technology Ltd.
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.